Medical Advocates
Zidovudine/Lamivudine (Combivir)
 
Journal Citations

General Reports
 Animal Studies
Dosing
 Viral Dynamics
 Adverse Events
Resistance
 Efficacy
 Post-Exposure Prophylaxis
 Therapeutic Strategies

 
Combivir Main Page Main New/Newsworthy Home Page
Last updated:  June 10, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
       
 
Differential Extracellular and Intracellular Concentrations of Zidovudine and Lamivudine in
Semen and Plasma of HIV-1-Infected Men.
Dumond JB, Reddy YS, Troiani L,et al
J Acquir Immune Defic Syndr. 2008 Mar 20
 Abstract

Zidovudine + lamivudine: new preparation. Fewer tablets required.
 (No Authors indicated)
 Prescrire Int 1999 Apr;8(40):39-40
 Abstract
Animal Studies
       
  Prenatal exposure to anti-HIV drugs: Neurobehavioral effects of zidovudine (AZT) + lamivudine
(3TC) treatment in mice.
Venerosi A, Valanzano A, Alleva E, Calamandrei G
Teratology 2001 Jan;63(1):26-37
Abstract  
Dosing
       
 
Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in
adolescents.
Flynn PM, Rodman J, Lindsey JC, et al 
Antimicrob Agents Chemother. 2007 Oct;51(10):3516-22.
 Abstract  

Intracellular Pharmacokinetics of Once vs. Twice Daily Zidovudine and Lamivudine
in Adolescents.
Flynn PM, Rodman J, Lindsey JC, et al 
Antimicrob Agents Chemother. 2007 Jul 30;
Abstract  
Viral Dynamics
       
 
Persistent Antiretroviral Activity of Nucleoside Analogues After Prolonged Zidovudine and
Lamivudine Therapy as Demonstrated by Rapid Loss of Activity After Discontinuation.
 Eron JJ Jr, Bartlett JA, Santana JL, et al 
J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1581-1583.
 Abstract  

Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations
in HIV-infected individuals.
Anderson PL, Kakuda TN, Kawle S, Fletcher CV.
AIDS. 2003 Oct 17;17(15):2159-68
 Abstract
Adverse Events
       
Bone Density
 
  Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine
plus abacavir or lopinavir/ritonavir.
Rivas P, Górgolas M, García-Delgado R, et al 
HIV Med. 2007 Dec 18
 Abstract
 
Cutaneous Disorders
 
  Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine,
or abacavir with lamivudine.
 Shlay JC, Sharma S, Peng G, et al 
J Acquir Immune Defic Syndr. 2008 May 1;48(1):53-62.
 Abstract
 
Hypersensitivity
 
  Recurrent hypersensitivity to Combivir.
 Winston A, McLean K.
 Int J STD AIDS 2002 Mar;13(3):213-4
 Abstract
 
Insulin Resistance
 
  Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination
antiretroviral therapy.
Blümer RM, van Vonderen MG, Sutinen J,et al  
AIDS. 2008 Jan 11;22(2):227-236.
 Abstract
Resistance
       
  Mechanisms by which G333D in HIV-1 Reverse Transcriptase Inhibitors Facilitates Dual
Resistance to Zidovudine and Lamivudine
Zelina S, Sheen CW, Radzio J, et al   
Antimicrob Agents Chemother. 2007 Oct 29;
Abstract  
Efficacy
       
 
The renaissance of fixed dose combinations: Combivir.
Portsmouth SD, Scott CJ.
Ther Clin Risk Manag. 2007 Aug;3(4):579-83.
 Abstract
 
Tolerability and Effectiveness of First-Line Regimens Combining Nevirapine and Lamivudine
Plus Zidovudine or Stavudine in Cameroon.
Laurent C, Bourgeois A, Mpoudi-Ngolé E, et al
 AIDS Res Hum Retroviruses. 2008 Mar 7
 Abstract
 
Virologic Response of Zidovudine, Lamivudine, and Tenofovir Disoproxil Fumarate
Combination in Antiretroviral-Naive HIV-1-Infected Patients.
Rey D, Krebs M, Partisani M, et al 
J Acquir Immune Defic Syndr. 2006 Oct 12;
 Abstract
 
Spontaneous recovery of hemoglobin and neutrophil levels in Japanese patients on a
long-term Combivir containing regimen.
Matsushita S, Yoshimura K, Kmura T, et al
J Clin Virol. 2005 Jul;33(3):188-93.
 Abstract
 
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.
 Robbins GK, De Gruttola V, Shafer RW, et al
N Engl J Med. 2003 Dec 11;349(24):2293-303.
 Abstract

Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in
antiretroviral treatment-naive HIV-1-infected adults: La Francilienne.
de Truchis P, Force G, Welker Y, et al.
J Acquir Immune Defic Syndr 2002 Oct 1;31(2):178-82
 Abstract

  
     
  A clinical trial using zidovudine and lamivudine plus indinavir triple therapy in Chinese
individuals with human immunodeficiency virus infection
 Cao Y, Zhang F, Mei S, et al.
 Zhonghua Nei Ke Za Zhi 2002 Feb;41(2):109-13
 Abstract		  
> "2"> Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and
lopinavir-ritonavir for HIV infection.
 Rabaud C, Burty C, Grandidier M, et al  
Clin Infect Dis. 2005 Jan 15;40(2):303-5.
 Abstract
Post-Exposure Prophylaxis
Therapeutic Strategies
       
HTLV-1 Associated Myelopathy
 
  A WEEK-IN-REVIEW FEATURED REPORT
FULL-TEXT ARTICLE
 Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy:
a randomised trial.
Taylor GP, Goon P, Furukawa Y,et al
Retrovirology. 2006 Sep 19;3:6
 Paper

Combivir Main Page Main New/Newsworthy Home Page

Combivir Journal Citations